Clinical Trial

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-06-25.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-18
Trial Details
NCT Number NCT02485015
Lead Sponsor The First People's Hospital of Changzhou
Conditions Stomach Neoplasms
Enrollment 80 participants
Start Date 2015-06
Primary Completion 2030-06 (estimated)
Study Completion 2033-06 (estimated)
Updated on ClinicalTrials.gov 2016-02-19